KALV Earnings

KALV reported its FY2026Q1 earnings on 2025-09-11, showcasing a revenue of 1.43M against an estimate of 2.09M, resulting in a -31.73% surprise. The EPS was 0, surpassing the expected -0.91 by 0% . The stock experienced a -3.77% price change on the earnings day and a -12.28% change over the next five days, reflecting market reactions to the results.

Following KALV's FY2026Q1 earnings announcement on 2025-09-11, the stock price moved by -3.77% on the day of the release. Over the subsequent five days, it saw a -12.28% change. Historically, KALV's stock price tends to shift by an average of -5.40% in the 10 days leading up to earnings and -3.48% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate KALV’s annual revenue to reach 20.37M, while the EPS is projected at -0.87. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 13.39% and EPS estimates Revise Downward by -1.26% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between KALV's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 13.39%, while EPS estimates moved Revise Downward by -1.26% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, KALV's stock price typically moves by -5.40% in the 10 days before its earnings and -3.48% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.87 and revenue of 20.37M.

The earnings call summary presents a mixed picture. While EKTERLY's early market adoption and strong focus on high-burden patients are positive, the lack of specific financial guidance and uncertainty around revenue projections and pricing in Germany introduce caution. The Q&A reveals concerns about demand fluctuations and management's reluctance to provide clear revenue guidance, which tempers overall optimism. The neutral sentiment reflects these balanced positive and negative factors, with no strong catalysts or deterrents to drive significant stock price movement in the short term.